Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo- controlled, randomized phase II trial

Ludwig Kappos,Giancarlo Comi,Hillel Panitch,Joel Oger,Jack P. Antel,Paul J. Conlon,Lawrence Steinman,Alexander Rae-Grant,John E. Castaldo,Nancy Eckert,Joseph B. Guarnaccia,Pamela Mills,Gary Johnson,Peter A. Calabresi,Carlo Pozzilli,S. Bastianello,Elisabetta Giugni,Tatiana Witjas,Patrick Cozzone,J. Pelletier,Dieter Pöhlau,H. Przuntek,V. Hoffmann,Christopher T. Bever,Eleanor Katz,M. Clanet,I. Berry,David Brassat,Irene Brunet,Gilles Edan,Pierre Duquette,Ernst-Wilhelm Radue,Dagmar Schött,Carmen Lienert,Alice Taksaoui,M. Rodegher,Massimo Filippi,Alan C. Evans,Pierre Bourgouin,Alex P. Zijdenbos,Shawki Salem,Nicholas Ling,David G. Alleva,Eric B. Johnson,Amitabh Gaur,Paul D. Crowe,Xin-Jun Liu

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo- controlled, randomized phase II trial

2000

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

Keywords:

Placebo
Immunology
Type 2 T-helper cell
Multiple sclerosis
Ligand
Medicine
Peptide
peptide ligand

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

453

Citations